Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA4534333
Max Phase: Preclinical
Molecular Formula: C20H16F4N4O4
Molecular Weight: 452.36
Molecule Type: Unknown
Associated Items:
ID: ALA4534333
Max Phase: Preclinical
Molecular Formula: C20H16F4N4O4
Molecular Weight: 452.36
Molecule Type: Unknown
Associated Items:
Canonical SMILES: O=C(Nc1ccc2[nH]c(=O)oc2c1)C(=O)N1CCN(c2ccc(C(F)(F)F)c(F)c2)CC1
Standard InChI: InChI=1S/C20H16F4N4O4/c21-14-10-12(2-3-13(14)20(22,23)24)27-5-7-28(8-6-27)18(30)17(29)25-11-1-4-15-16(9-11)32-19(31)26-15/h1-4,9-10H,5-8H2,(H,25,29)(H,26,31)
Standard InChI Key: DHOPUVMTPDUDAN-UHFFFAOYSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Unknown | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 452.36 | Molecular Weight (Monoisotopic): 452.1108 | AlogP: 2.57 | #Rotatable Bonds: 2 |
Polar Surface Area: 98.65 | Molecular Species: NEUTRAL | HBA: 5 | HBD: 2 |
#RO5 Violations: 0 | HBA (Lipinski): 8 | HBD (Lipinski): 2 | #RO5 Violations (Lipinski): 0 |
CX Acidic pKa: 9.51 | CX Basic pKa: 0.96 | CX LogP: 2.93 | CX LogD: 2.92 |
Aromatic Rings: 3 | Heavy Atoms: 32 | QED Weighted: 0.46 | Np Likeness Score: -1.68 |
1. Anan K, Masui M, Tazawa A, Tomida M, Haga Y, Kume M, Yamamoto S, Shinohara S, Tsuji H, Shimada S, Yagi S, Hasebe N, Kai H.. (2019) Discovery of NR2B-selective antagonists via scaffold hopping and pharmacokinetic profile optimization., 29 (9): [PMID:30833109] [10.1016/j.bmcl.2019.02.017] |
Source(1):